NCI COMPASS-Comprehensive Oncologic Molecular Pathology and Sequencing Service

点击翻译按钮获取中文摘要

The Molecular Diagnostics Section is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on pathology materials from NIH patients. The newly established COMPASS program is to expand next generation sequencing to support clinical and research in CCR. In FY22 (July 2021 - June 2022), the NGS lab run 1376 TSO500, whole exome sequencing, and RNA exome sequencing tests. These results have provided support of precision pathological diagnosis and precision oncology for 75 clinical protocols from NCI and 9 protocol from NIAID, NIAMS, NIDDK, NHGRI including CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. We are also screening the targets in patients from CCR intramural clinics for NCI-MATCH. The program also developed and deployed whole exome sequencing, RNA exome sequencing assays into clinical service during FY22. The whole genome sequencing is in use for clinical and research especially for supporting CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. The cell-free circulating DNA NGS assay is still in development. The COMPASS program provided the great opportunities of training or continuing education for both pathology and oncology teams especially next generation of pathologists and physician scientists by running weekly NGS technical review conference, weekly molecular pathology/neuro-oncology conference, and weekly molecular pathology/pediatric oncology conference to discuss molecular finding, treatment, and beyond particular patient or mutation.